Form 4 for KNSA Kiniksa Pharmaceuticals International, plc
Accepted 2026-03-11 00:00:00 ET · period of report 2026-03-09 · accession 0001835458-26-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-11 | 2026-03-09 | KNSA | Ragosa Mark | CFO | M - OptEx | $20.69 | +36.7K | 48.8K | +304% | +$759.8K |
| DM | 2026-03-11 | 2026-03-09 | KNSA | Ragosa Mark | CFO | S - Sale+OE | $45.92 | -36.7K | 30.8K | -54% | -$1.69M |
| DM | 2026-03-11 | 2026-03-09 | KNSA | Ragosa Mark | CFO | M - OptEx | $0.00 | -36.7K | 18.4K | -67% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Share | 2026-03-09 | M | A | 2,036 | $22.89 | 14,122 | D | — | — | |
| 2 | Common | Class A Ordinary Share | 2026-03-09 | M | A | 10,513 | $17.76 | 24,635 | D | — | — | |
| 3 | Common | Class A Ordinary Share | 2026-03-09 | M | A | 13,813 | $18.06 | 38,448 | D | — | — | |
| 4 | Common | Class A Ordinary Share | 2026-03-09 | M | A | 10,360 | $26.74 | 48,808 | D | — | — | |
| 5 | Common | Class A Ordinary Share | 2026-03-09 | S | D | 18,741 | $46.24 | 12,086 | D | — | — | (F3) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.89 and $46.79. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff fullinformation regarding the number of Shares sold at each price. |
| 6 | Common | Class A Ordinary Share | 2026-03-09 | S | D | 17,981 | $45.58 | 30,827 | D | — | — | (F2) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $44.885 and $45.88. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |
| 7 | Derivative | Share Option | 2026-03-09 | M | D | 2,036 | $0.00 | 0 | D | $22.89 · — to 2031-03-15 | 2,036 Class A Ordinary Share | (F4) The option is fully vested and exercisable. |
| 8 | Derivative | Share Option | 2026-03-09 | M | D | 10,360 | $0.00 | 22,790 | D | $26.74 · — to 2034-08-31 | 10,360 Class A Ordinary Share | (F7) The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2024. |
| 9 | Derivative | Share Option | 2026-03-09 | M | D | 13,813 | $0.00 | 19,337 | D | $18.06 · — to 2034-03-31 | 13,813 Class A Ordinary Share | (F6) The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2024. |
| 10 | Derivative | Share Option | 2026-03-09 | M | D | 10,513 | $0.00 | 18,396 | D | $17.76 · — to 2033-08-31 | 10,513 Class A Ordinary Share | (F5) The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023. |